Umfang:
Online-Ressource (digital)
ISBN:
9781441901316
,
9781441901309
Serie:
SpringerLink
Inhalt:
Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance. Main features of the book:Anticancer drug development and regulatory processes.Strategies to suppress tumor angiogenesis and metastasis, overcome multi-drug resistance in cancer, target telomerase and apoptosis pathways.Therapeutic approaches to employ monoclonal antibody and cancer vaccines.Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling.Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs.Utilization of bioimaging and HIF-1 knockout animal models in cancer study.Clinical trials designs and principles
Anmerkung:
Includes bibliographical references and index
,
Pharmaceutical Perspectives of Cancer Therapeutics; Preface; About the Editors; Contents; Contributors; Tumor Microvasculature and Microenvironment: Therapeutic Targets for Inhibition of Tumor Angiogenesis and Metastasis; 1 Introduction; 2 Tumor Microvasculature and Microenvironment; 2.1 Tumor Microvasculature; 2.2 Tumor Microenvironment; 3 Angiogenesis; 3.1 Physiological Angiogenesis; 3.2 Pathological Angiogenesis; 3.3 Angiogenic Switch; 4 Therapeutic Approaches for Inhibition of Tumor Angiogenesis; 4.1 From the Emerging Concept that Tumor Growth Is Angiogenesis-Dependent to Clinical Trials
,
4.2 Category of Angiogenesis Inhibitors4.2.1 Direct Angiogenesis Inhibitors; 4.2.2 Indirect Angiogenesis Inhibitors; 4.2.3 Endogenous Angiogenesis Inhibitors; 4.2.4 Angiogenesis Inhibitors That Block the Signaling Transduction Pathway; 4.2.5 Angiogenesis Inhibitors That Prevent ECM Breakdown; 4.2.6 Miscellaneous Angiogenesis Inhibitors; 4.3 Anti-angiogenic Therapy and Pharmaceutic Targets; 4.3.1 VEGF as a Therapeutic Target; 4.3.2 bFGF as a Therapeutic Target; 4.3.3 HIF-1 as a Therapeutic Target; 4.3.4 Other Targets for Angiogenesis Inhibition
,
4.4 Gene Therapy and Other Biological Therapeutic Approaches for Anti-angiogenesis4.4.1 Gene Therapy Using Angiostatin; 4.4.2 Gene Therapy Target VEGF; p16 Inhibits VEGF-Mediated Angiogenesis In Vitro; p16 InhibitsVEGF-Mediated Angiogenesis In Vivo; 4.4.3 Other Targets and Protein Replacement Therapy for Anti-angiogenesis; 5 Tumor Progression, Metastasis, and Their Therapeutic Targets; 5.1 Angiogenesis as the Prerequisite for Tumor Progression and Metastasis; 5.2 Therapeutic Targets for Tumor Vasculature; 5.3 Therapeutic Target for Tumor Microenvironment - Stroma
,
5.4 Therapeutic Target for Hypoxia and HIF-15.5 Therapeutic Target for Cancer Stem Cells; 6 Challenges and Future Prospects; 6.1 Unsolved Problems; 6.1.1 Resistance to Anti-angiogenesis Therapy; 6.1.2 Toxicity Associated with Anti-angiogenic Drugs; 6.1.3 Lack of Appropriate Animal Models; 6.2 Future Directions; 6.2.1 Establishment of Reliable Biomarkers; 6.2.2 Target Stroma and Cancer Stem Cells; 6.2.3 Combination Therapy; 6.2.4 Novel Therapies; Anti-neovascular Therapy; Targeting Key Transduction Pathway Kinase; Cancer ''Normalization''; Discovery of New Drugs by Chemical Genomics
,
ReferencesAnticancer Drug Development; 1 Introduction; 2 Approaches in Anticancer Drug Therapy; 2.1 Drug Development Paradigms for Molecularly Targeted Agents; 2.1.1 Facilitating Apoptosis; 2.1.2 Inhibiting Metastasis; 2.1.3 Inhibiting Angiogenesis; 2.1.4 Antibodies Against Tumor-Specific Antigens; 2.2 Pharmacogenetics and Metabolomics; 2.3 Modulators, Sensitizers, and Supportive Cancer-Care Agents; 3 Anticancer Drug Development Process; 3.1 Historical Background; 3.2 Discovery of Potential Drug Candidates; 3.3 Preclinical Evaluation; 3.3.1 Preclinical Efficacy Screening
,
3.3.2 Preclinical Toxicity Studies
Weitere Ausg.:
ISBN 9781441901309
Weitere Ausg.:
Buchausg. u.d.T. ISBN 978-1-441-90130-9
Sprache:
Englisch
DOI:
10.1007/978-1-4419-0131-6
URL:
Volltext
(lizenzpflichtig)
